Compositions Comprising Hypoxia Inducible Factor-1 Alpha and Methods of Using the Same

Abstract

Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1α). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.

What is claimed is: 
     
         1 . A therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1α). 
     
     
         2 . The therapeutic of  claim 1 , wherein HIF-1α is encoded by a nucleotide sequence as set forth in SEQ ID NO:1, a nucleotide sequence as set forth in SEQ ID NO:3, a nucleotide sequence as set forth in SEQ ID NO:5, a nucleotide sequence that is 95% identical or greater to SEQ ID NO:1, a nucleotide sequence that is 95% identical or greater to SEQ ID NO:3, or a nucleotide sequence that is 95% identical or greater to SEQ ID NO:5. 
     
     
         3 . The therapeutic of  claim 2 , wherein HIF-1α is encoded by the nucleotide sequence as set forth in SEQ ID NO:5. 
     
     
         4 . The therapeutic of  claim 2 , further comprising an amino acid sequence as set forth in SEQ ID NO:2, an amino acid sequence as set forth in SEQ ID NO:4, an amino acid sequence as set forth in SEQ ID NO:6, an amino acid sequence that is 95% identical or greater to SEQ ID NO:2, an amino acid sequence that is 95% identical or greater to SEQ ID NO:4, or an amino acid sequence that is 95% identical or greater to SEQ ID NO:6. 
     
     
         5 . The therapeutic of  claim 3 , further comprising an amino acid sequence as set forth in SEQ ID NO:6. 
     
     
         6 . The therapeutic of  claim 1 , wherein HIF-1α is mutated such that HIF-1α cannot be hydroxylated in a cell. 
     
     
         7 . The therapeutic of  claim 6 , wherein a proline residue of HIF-1α cannot be hydroxylated in the cell. 
     
     
         8 . The therapeutic of  claim 1 , further comprising a pharmaceutically acceptable excipient. 
     
     
         9 . A method of treating hypoxia or ischemia in a subject in need thereof, the method comprising administering the vaccine of  claim 1  to the subject. 
     
     
         10 . The method of  claim 9 , wherein administering the vaccine includes electroporation. 
     
     
         11 . The method of  claim 9 , wherein administering the vaccine includes at least one of intramuscular administration and intradermal administration. 
     
     
         12 . The method of  claim 9 , wherein the hypoxia or ischemia is associated with critical limb ischemia, peripheral artery disease, wound healing, a vascular disease, a circulatory disease, coronary artery disease, cardiovascular disease, or diabetes. 
     
     
         13 . The method of  claim 12 , wherein the hypoxia or ischemia is associated with critical limb ischemia. 
     
     
         14 . The method of  claim 9 , wherein at least one of capillary density, collateral vessel formation or vessel size is increased in the subject administered the vaccine as compared to a subject not administered the vaccine. 
     
     
         15 . The method of  claim 9 , wherein tissue perfusion is increased in the subject administered the vaccine as compared to a subject not administered the vaccine. 
     
     
         16 . The method of  claim 9 , wherein tissue necrosis is decreased in the subject administered the vaccine as compared to a subject not administered the vaccine. 
     
     
         17 . A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: SEQ ID NO:5 and a nucleotide sequence that is 95% identical or greater to SEQ ID NO:5. 
     
     
         18 . The nucleic acid molecule of  claim 17 , wherein the nucleotide sequence is a plasmid. 
     
     
         19 . An amino acid molecule comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:6 and an amino acid sequence that is 95% identical or greater to SEQ ID NO:6.